Optimizing care for high-risk neuroblastoma patients treated with dinutuximab: Challenges for the multidisciplinary team.
J Oncol Pharm Pract
; 26(7): 1721-1724, 2020 Oct.
Article
in En
| MEDLINE
| ID: mdl-32660378
ABSTRACT
Current treatment protocols for high-risk neuroblastoma include high-dose chemotherapy, surgery, stem cell transplantation and radiation. Recently, dinutuximab, a chimeric monoclonal antibody, specifically targeting the disialoganglioside highly expressed on neuroblastoma cells, has been licensed. Its incorporation in maintenance therapy represents a promising treatment approach. The introduction of its use was a challenge for the entire multidisciplinary team in our pediatric hematology and oncology ward just as for the pharmacy team. An overview of the key points that were observed is presented.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Patient Care Team
/
Antibodies, Monoclonal
/
Neuroblastoma
Type of study:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Limits:
Child
/
Humans
Language:
En
Journal:
J Oncol Pharm Pract
Journal subject:
FARMACIA
Year:
2020
Document type:
Article
Affiliation country:
Belgium